In the last trading session, 1.15 million Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) shares changed hands as the company’s beta touched 2.07. With the company’s per share price at $37.3 changed hands at $1.32 or 3.67% during last session, the market valuation stood at $274.42M. TNXP’s last price was a discount, traded about -248.53% off its 52-week high of $130.00. The share price had its 52-week low at $6.76, which suggests the last value was 81.88% up since then. When we look at Tonix Pharmaceuticals Holding Corp’s average trading volume, we note the 10-day average is 0.73 million shares, with the 3-month average coming to 953.49K.
Analysts gave the Tonix Pharmaceuticals Holding Corp (TNXP) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended TNXP as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Tonix Pharmaceuticals Holding Corp’s EPS for the current quarter is expected to be -1.88.
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) trade information
Instantly TNXP was in green as seen at the end of in last trading. With action 4.57%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -45.94%, with the 5-day performance at 4.57% in the green. However, in the 30-day time frame, Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) is -6.23% down. Looking at the short shares, we see there were 1.13 million shares sold at short interest cover period of 0.85 days.
Tonix Pharmaceuticals Holding Corp (TNXP) estimates and forecasts
Year-over-year growth is forecast to reach 20.46% up from the last financial year.
Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of 2.6M. 3 analysts are of the opinion that Tonix Pharmaceuticals Holding Corp’s revenue for the current quarter will be 3.3M. The company’s revenue for the corresponding quarters a year ago was 2.21M and 2.82M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 17.75%. The estimates for the next quarter sales put growth at 16.94%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 73.03%. The 2025 estimates are for Tonix Pharmaceuticals Holding Corp earnings to increase by 93.08%, but the outlook for the next 5-year period is at 88.07% per year.
TNXP Dividends
Tonix Pharmaceuticals Holding Corp is expected to release its next quarterly earnings report on 2025-May-12.
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.05% of Tonix Pharmaceuticals Holding Corp shares while 7.03% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 7.04%. There are 7.03% institutions holding the Tonix Pharmaceuticals Holding Corp stock share, with PRUDENTIAL FINANCIAL INC the top institutional holder. As of 2024-06-30, the company held 0.0239% of the shares, roughly 97707.0 TNXP shares worth $68141.0.
ALYESKA INVESTMENT GROUP, L.P. holds the second largest percentage of outstanding shares, with 0.0153% or 62500.0 shares worth $43588.0 as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund . With 88.86 shares estimated at $3.31 million under it, the former controlled 1.21% of total outstanding shares. On the other hand, Fidelity Concord Street Trust-Fidelity Extended Market Index Fund held about 0.42% of the shares, roughly 30.75 shares worth around $1.15 million.
